Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) is a respiratory virus that infects the nose, throat, and lungs. Symptoms of RSV can appear similar to a cold, which can make it difficult to distinguish from the common cold or other respiratory viruses (like the flu or COVID-19). RSV spreads in the fall and winter along with other respiratory viruses. Some people with an RSV infection, especially infants younger than six months of age and adults who are older or have certain risk factors, are more susceptible to severe illness.1 While RSV is one of the most common respiratory viruses, there are many others that also occur during the same seasonal pattern, such as human metapneumovirus (hMPV).2 A RSV combination vaccine could help provide an “all-in-one" option for multiple respiratory viruses, especially as RSV and hMPV are common viruses causing hospitalization for many people each year.3
RSV ~64 million cases and 160,000 deaths in total each year worldwide4
hMPV ~11.1 million global cases and 300 deaths due to hMPV infection among children under five5
8M+ worldwide deaths annually due to all human respiratory viruses and respiratory disease6
Currently, commercially available vaccines only target the RSV virus. Our technology could enable the combination of multiple respiratory virus antigens into a single vaccine that protects against RSV as well as other viruses such as human metapneumovirus (hMPV), and hPIV which can help improve vaccination rates for multiple respiratory illnesses.
With one shot for RSV and other respiratory viruses, we have the potential to reduce the number of injections needed, reduce the burden on healthcare systems, and meet consumer demand for all-in-one solutions.
Pipeline
Check out our vaccine candidates for respiratory, viral infections and bacterial diseases.
Partnership
We create high-impact partnerships to drive vaccine innovation.
Centers for Disease Control and Prevention. About RSV [Internet]. Available from: https://www.cdc.gov/rsv/about/index.html. Accessed 18 September 2025.
Centers for Disease Control and Prevention. About Human Metapneumovirus. Available from: https://www.cdc.gov/human-metapneumovirus/about/index.html. Accessed 18 September 2025.
Bhasin A, et al. The burden of RSV, hMPV, and PIV amongst hospitalized adults in the United States from 2016 to 2019. J Hosp Med. 2024 Jul;19(7):581-588. doi: 10.1002/jhm.13320. Epub 2024 Mar 10.
National Institute of Allergy and Infectious Disease. Respiratory Syncytial Virus (RSV). Available from: https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv. Accessed 18 September 2025.
Meher M, et al. Global surge of human metapneumovirus (hMPV) and its interactions with microbiome to disease severity. J Infect Public Health. Volume 19, Issue 1, January 2026, 103024. DOI: 10.1016/j.jiph.2025.103024
Forum of International Respiratory Societies. The global impact of respiratory disease. Third Edition. European Respiratory Society, 2021.